Bifunctional cytotoxic agents containing the CTI pharmacophore

Patent metadata

Field	Value
Publication number	US-11365263-B2
Application number	US-202017091097-A
Country	US
Kind code	B2
Filing date	Nov 6, 2020
Priority date	Mar 20, 2015
Publication date	Jun 21, 2022
Grant date	Jun 21, 2022

Abstract

The present invention is directed to novel bifunctional CTI-CTI and CBI-CTI dimers of the formula:F1-L1-T-L2-F2where F1, L1, T, L2 and F2 are as defined herein, useful for the treatment for proliferative diseases, where the inventive dimers can function as stand-alone drugs, payloads in antibody-drug-conjugates (ADCs), and linker-payload compounds useful in connection with the production or administration of such ADCs; and to compositions including the aforementioned dimers, linker-payloads and ADCs, and methods for using these dimers, linker-payloads and ADCs, to treat pathological conditions including cancer.

First claim

We claim:

1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (IIIA):
AB-(L-P) 1-20   (IIIA)

or a pharmaceutically acceptable salt or solvate thereof,
wherein:
AB is an antibody:
P is:
F 1 -L 1 -T-L 2 -F 2

wherein:
F 1 and F 2 are each independently selected from ring systems A, B, C and D:

where:
each R is independently selected from the group consisting of H, —C 1 -C 20 alkyl, —C 2 -C 6 alkenyl, —C 2 -C 6 alkynyl, halo, deuterium, hydroxyl, alkoxy, —NH 2 , —NH(C 1 -C 8 alkyl), —N(C 1 -C 8 alkyl) 2 , —NO 2 , —C 6 -C 14 aryl and —C 6 -C 14 heteroaryl, or wherein two or more R optionally join to form a ring or rings, and wherein said —C 6 -C 14 aryl and —C 6 -C 14 heteroaryl are optionally substituted with 1 to 5 substituents independently selected from —C 1 -C 10 alkyl, —C 1 -C 10 alkoxy, -halo, —C 1 -C 10 alkylthio, -trifluoromethyl, —NH 2 , —NH(C 1 -C 8 alkyl), —N(C 1 -C 8 alkyl) 2 , —C 1 -C 10 alkyl-N(C 1 -C 8 alkyl) 2 , —C 1 -C 3 alkylthio, —NO 2 or —C 1 -C 10 heterocyclyl, for each ring system in which R appears:
each V 1 is independently a bond, O, N(R) or S, for each ring system in which V 1 appears:
each V 2 is independently O, N(R) or S, for each ring system in which V 2 appears:
W 1 and W 2 are each independently H, —C 1 -C 5 alkyl, -phenyl, —C(O)OR, —C(O)SR, —C(O)NHN(R) 2 or —C(O)N(R) 2 for each ring system in which W 1 and W 2 appear;
each X is independently selected from —OH, —O-acyl, azido, halo, cyanate, thiocyanate, isocyanate, thioisocyanate, or

for each ring system in which X appears;
each Y is independently selected from a bond, H, —C(O)R A , —C(S)R A , —C(O)OR A , —S(O) 2 OR A , —C(O)N(R A ) 2 , —C(S)N(R A ) 2 , glycosyl, —NO 2 , —P(O)(OR A ) 2 , an amino acid and a peptide for each ring system in which Y appears, wherein each R A is independently selected from H, —C 1 -C 20 alkyl, —C 1 -C 8 heteroalkyl, —C 6 -C 14 aryl, aralkyl, —C 1 -C 10 heterocyclyl, —C 3 -C 8 carbocyclyl, —C 1 -C 20 alkylN(R) 2 , —C 1 -C 20 alkylene, —C 1 -C 8 heteroalkylene, —C 6 -C 14 arylene, aralkylene, —C 1 -C 10 heterocyclo, —C 3 -C 8 carbocyclo and —C 1 -C 20 alkylN(R)—, and R F where said R A is optionally substituted with 1 to 3 substituents independently selected from R, and wherein at least one Y-containing Ring System is present and is divalent and is bonded to L,
R F is —N(R 6 )QN(R 5 )C(O)— and is bonded to L at the carbonyl adjacent N(R 5 ), wherein R 5 and R 6 are each independently selected from the group consisting of H, —C 1 -C 8 alkyl, —C 1 -C 8 heteroalkyl, —C 6 -C 14 aryl, -aralkyl, —C 1 -C 10 heterocyclyl and —C 3 -C 8 carbocyclyl, or R 5 or R 6 loins with a substituted carbon on Q to form a —C 1 -C 10 heterocyclic or —C 6 -C 14 heteroaryl ring, or R 5 and R 6 join together to form a —C 1 -C 10 heterocyclic or —C 6 -C 14 heteroaryl ring system, and where Q is —C 1 -C 8 alkylene-, —C 1 -C 8 heteroalkylene-, —C 6 -C 14 arylene-, -aralkylene-, —C 1 -C 10 heterocyclo- or —C 3 -C 8 carbocyclo-, wherein Q, R 5 and R 6 are each independently optionally substituted with 1 to 3 substituents independently selected from R:
each Z is independently selected from the group consisting of H, —C 1 -C 8 alkyl, —C 1 -C 8 heteroalkyl, —C 6 -C 14 aryl, -aralkyl, —C 1 -C 10 heterocyclyl, —C 3 -C 8 carbocyclyl, —C(O)OC 1 -C 8 alkyl, —C(O)N(C 1 -C 8 alkyl) 2 , —C(O)OH, —C(O)NHNH 2 and —C(O)-halo, and wherein said C 1 -C 8 alkyl, —C 1 -C 8 heteroalkyl, —C 6 -C 14 aryl, -aralkyl, —C 1 -C 10 heterocyclyl, —C 3 -C 8 carbocyclyl, —C(O)OC 1 -C 8 alkyl, —C(O)N(C 1 -C 8 alkyl) 2 , —C(O)OH, —C(O)NHNH 2 and —C(O)-halo are each optionally substituted with 1 to 3 substitutents independently selected from R, for each ring system in which Z appears:
L 1 and L 2 are each independently selected from a direct bond
T is
—C(A 1 )X 1 -T 2 -X 1 C(B 1 )—, where T 2 is:

wherein each X 1 is independently a bond, —NR E —, —O— or —S—, wherein A 1 and B 1 are each independently ═O or ═S, wherein R 1 , R 2 , R 3 , and R 4 are each independently R E or R 1 and R 2 form a ring system, or R 3 and R 4 form a ring system, or both R 1 and R 2 , and R 3 and R 4 , each independently form ring systems, or R 1 and R 3 form a ring system, or R 2 and R 4 form a ring system, or both R 1 and R 3 , and R 2 and R 4 , each independently form ring systems, where said ring systems are independently selected from —C 1 -C 10 heterocyclyl or —C 3 -C 8 carbocyclycl, or R 1 , R 2 , R 3 and R 4 are each bonds to different carbons on D, wherein q and j are each independently an integer from 0 to 50 and m is an integer from 1 to 50, and wherein D is selected from the group consisting of —C 1 -C 10 heterocyclo and —C 3 -C 8 carbocyclo, where said —C 1 -C 10 heterocyclo and —C 3 -C 8 carbocyclo are optionally substituted with —R E , —C(O)R E , —C(O)OR E , —N(R E ) 2 , —N(R)C(O)R E or —N(R)C(O)OR E , and D is additionally optionally substituted by 1 to 2 R,
wherein each R E is independently selected from the group consisting of H, —C 1 -C 8 alkyl, —C 1 -C 8 heteroalkyl, -aryl, -aralkyl, —C 1 -C 10 heterocyclyl, —C 3 -C 8 carbocyclyl, —C(O)OC 1 -C 8 alkyl, —C(O)N(C 1 -C 8 alkyl) 2 , and —C(O)-halo, and wherein each R E is optionally substituted with 1 to 3 substitutents independently selected from R;
L is L A -L B -(L C ) 1-3 wherein an L C is bound to Y;
L A is selected from: a bond to AB, —NR-(bond to AB), -heteroaryl-(bond to AB),

L B is L B1 -L B2 -L B3
wherein L B1 is absent or is one or more components selected from the grouj consisting of —C(O)—, —C(S)—, —C(O)NR—, —C(O)C 1 -C 6 alkyl-, —C(O)NRC 1 -C 6 alkyl-, —C 1 -C 6 alkyl(OCH 2 CH 2 ) 1-6 —, —C(O)C 1 -C 6 alkylNRC(O)—, —C(O)C 1 -C 6 alkyl(OCH 2 CH 2 ) 1-6 —, —C 1 -C 6 alkyl(OCH 2 CH 2 ) 1-6 -C(O)—, —C 1 -C 6 alkyl-S—S—C 1 -C 6 alkylNRC(O)CH 2 —, —C 1 -C 6 alkyl(OCH 2 CH 2 ) 1-6 NRC(O)CH 2 —, —C(O)C 1 -C 6 alkyl-NRC(O)C 1-6 alkyl-, —N═CR-phenyl-O—C 1 -C 6 alkyl-, —N═CR-phenyl-O—C 1 -C 6 alkyl-C(O)—, —C(O)—C 1 -C 6 alkyl(OCH 2 CH 2 ) 1-6 NRC(O)—, —C(O)C 1 -C 6 alkyl-phenyl(NR—C(O)C 1 -C 6 alkyl) 1-4 -, —C(O)C 1 -C 6 alkyl(OCH 2 CH 2 ) 1-6 —NRC(O)C 1 -C 6 alkyl-, —C 1 -C 6 alkyl-, —S—, —C(O)—CH(NR—C(O)C 1 -C 6 alkyl)-C 1 -C 6 alkyl- and (—CH 2 —CH 2 —O—) 1-20 ;
L B2 is AA 0-12 , wherein AA is a natural amino acid- or a non-natural amino acid;
L B3 is p-aminobenzoic acid, p-aminobenzyloxycarbonyl, —C(O)(CH 2 ) 0-50 C(O)— or absent,
L C is absent or is independently selected from the group consisting of —C 1 -C 6 alkylene-, —NRC 3 -C 8 -heterocyclylNR—, —NRC 3 -C 3 -carbocyclylNR—, —NRC 1 -C 6 alkylNR—, —NRC 1 -C 6 alkylene-, —S—, —NR—, —NRNR—, —O(CR 2 ) 1-4 S—S(CR 2 ) 1-4 N(R)—, —NRC 1 -C 6 -alkylenephenyleneNR—, —NRC 1 -C 6 alkylenephenyleneSO 2 NR—, —OC 1 -C 6 alkylS-SC 1 -C 6 alkylC(COOR)NR—,

wherein
X A is CR or N,
X B is CH, CR(C(R) 2 ) 1-3 NR, CR(C(R) 2 ) 1-30 , CR(C(R) 2 ) 1-3 C(O)NR, CR—(C(R) 2 ) 1-3 C(O)NRNR, CR(C(R) 2 ) 1-3 SO 2 NR, CR(C(R) 2 ) 1-3 NRNR, CR(C(R) 2 ) 1-3 NRC(O) or N,
each X C is R:
each X D is —(CH 2 ) 1-5 —, or is absent;
X E is O, S, C(R

Assignees

• Pfizer

Inventors

• Maderna Andreas
• Subramanyam Chakrapani
• Tumey Lawrence N
• Chen Zecheng
• Casavant Jeffrey M

Classifications

• A61K47/6803

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title

• C07K16/32 Primary

  against translation products of oncogenes · CPC title

• C07D495/04

  Ortho-condensed systems · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K31/407 Primary

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title